PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2019
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms PROVIDE-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jan 2019 Planned End Date changed from 17 Jun 2019 to 1 Jul 2019.
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.
- 28 Feb 2018 Planned End Date changed from 30 Jun 2018 to 17 Jun 2019.